H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsJul 17 12:38 ET · Ratings

Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion

TipRanksJul 17 12:27 ET

Express News | HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target

BenzingaJul 17 06:35 ET

Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form

MT NewswiresJul 16 08:39 ET

Express News | Annovis Bio Granted FDA Approval To Transition To New Crystal Form Of Buntanetap

BenzingaJul 16 08:00 ET

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

Annovis BioJul 16 00:00 ET